New CAR-T therapy aims to tackle Hard-to-Treat hodgkin lymphoma
NCT ID NCT06090864
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study tests a new type of immunotherapy called CAR-T cells, which are specially engineered to recognize and attack CD30, a protein found on Hodgkin lymphoma cells. The trial enrolls up to 31 adults whose cancer has returned or not responded to standard treatments. Participants receive chemotherapy to prepare their immune system, then an infusion of the modified cells. The goal is to find a safe dose and see if it can control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATLCAR.CD30.CCR4 cells (a type of CAR-T cell therapy that targets CD30 on cancer cells)
- What this could lead to
- If successful, this could provide a new treatment option for patients with Hodgkin lymphoma that has returned or not responded to standard therapies, potentially improving survival without the severe long-term side effects of current treatments.
- What could go wrong
- This is an early-phase trial with only 31 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- Can a smart immune cell with a kill switch beat tough lymphomas?